uniQure (NASDAQ:QURE) Receives $33.88 Consensus Target Price from Analysts

uniQure (NASDAQ:QURE) has been assigned an average recommendation of “Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $33.88.

Several brokerages recently weighed in on QURE. Leerink Partners lifted their price target on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. Mizuho increased their price target on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Royal Bank of Canada lifted their price objective on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. Finally, Stifel Nicolaus upped their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $13.99 on Thursday. The stock has a market cap of $681.91 million, a price-to-earnings ratio of -2.82 and a beta of 0.41. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The company has a 50 day simple moving average of $11.83 and a two-hundred day simple moving average of $8.24. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, analysts predict that uniQure will post -3.74 earnings per share for the current year.

Insider Buying and Selling

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

Hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. grew its stake in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of uniQure during the 3rd quarter worth approximately $444,000. FMR LLC grew its position in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of uniQure in the third quarter valued at approximately $7,360,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in uniQure during the third quarter worth approximately $283,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.